상세 보기
mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma
- Sangro, Bruno;
- Kudo, Masatoshi;
- Erinjeri, Joseph;
- Qin, Shukui;
- Ren, Zhenggang;
- ... Tak, Won Young;
- 외 14명
Citations
WEB OF SCIENCE
1- 제목
- mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma
- 저자
- Sangro, Bruno; Kudo, Masatoshi; Erinjeri, Joseph; Qin, Shukui; Ren, Zhenggang; Chan, Stephen; Arai, Yasuaki; Heo, Jeong; Mai, Ahn; Escobar, Jose; Chuken, Yamil Alonso Lopez; Yoon, Jung-Hwan; Tak, Won Young; Suttichaimongkol, Tanita; Bouattour, Mohamed; Lin, Shi-Ming; Zotkiewicz, Magdalena; Ali, Sajid; Cohen, Gordon; Lencioni, Riccardo
- 발행일
- 2024-06
- 유형
- Meeting Abstract
- 권
- 80
- 페이지
- S3 ~ S3
- 언어
- ENG
- 출판사
- ELSEVIER
- 발행국가
- 네덜란드
- ISSN
- E 1600-0641
P 0168-8278